Facebook Twitter Gplus YouTube Google Maps RSS
 
 
Home » Bad Drug » Archive for category "Yaz/Yasmin/Ocella Birth Control"

Archive for the ‘Yaz/Yasmin/Ocella Birth Control’ Category:


Settlement Figures Rise in Yaz and Yasmin Lawsuits

More cases against Bayer, maker of Yaz and Yasmin, have begun to settle. Currently 651 cases have settled, which averages around $218,000 per case, where women suffered from life threatening blood clots, according to Bloomberg News. Thousands more cases await trial or settlement and until April 10th the drug did not have a heightened warning

Read More::

Bayer Settles 651 Yaz Blood Clot Claims for $142 Million

Bayer continues to settle Yaz/Yasmin birth control lawsuits involving blood clots that caused deep vein thrombosis or pulmonary embolism.  Bayer reported in its 1st quarter Stockholders’ Newsletter 2012 that it reached an agreement to settle the claims of 651 plaintiffs for a total amount of $142 million, for an average of $218,000 a case.  This

Read More::

Bayer Pays Over $110 Million to Settle Yaz Birth Control Cases

Bayer will pay at least $110 million to settle about 500 lawsuits wherein plaintiffs allege that Yaz/Yasmin birth control pills caused serious injuries of which Bayer knew, or should have known, and failed to warn, reports Bloomberg.  Bayer officials agreed to pay an average of about $220,000 a case to resolve claims in involving fatal

Read More::

New Birth Control Label Warns of Increased Blood Clot Risk

The U.S. Food and Drug Administration (FDA) has completed its review of studies involving drospirenone-containing birth control pills, such as Yaz and Yasmin and has concluded that these types of birth control pills increase the risk for dangerous blood clot.  As a result, the FDA is requiring a label change to include this information. The revised

Read More::

Stanford doctor in birth control vote had ties to pill’s maker

California Watch by Erica Perez  –  A watchdog group is calling on the Food and Drug Administration to throw out a joint committee’s vote in support of a controversial oral contraceptive because four members of the committee – including a Stanford University professor of obstetrics and gynecology – had ties to the maker of the

Read More::

Why Did the FDA Allow Five Members to Sit on Yaz Birth Control Advisory Panel Despite Conflicts of Interest

In December 2011, a U.S. Food and Drug Administration (FDA) advisory panel voted 15-11 that the benefits of drospirenone-containing birth control pills, such as Yaz and Yasmin, outweigh the risks. Interestingly, though, an investigation by the Washington Monthly and the British Medical Journal (BMJ) found that at least four members of the committee have either done work for the drugs’

Read More::

The Yaz Men: Members of FDA panel reviewing the risks of popular Bayer contraceptive had industry ties

- Washington Monthly  by Jeanne Lenzer and Keith Epstein Last month, the U.S. Food and Drug Administration convened a committee of medical experts to weigh new evidence concerning the potential dangers of drospirenone, a synthetic hormone contained in popular birth control pills including Bayer AG’s Yaz and Yasmin. In a decision that helped ensure the

Read More::

Yaz Birth Control Case Ordered to Mediation

The first Yaz pulmonary embolism lawsuit that was scheduled to begin trial January 9, 2012 will not begin as planned.  The Honorable David Herndon, who is the presiding judge on many Bayer birth control pill lawsuits, ordered the case to mediation.   “This is a good sign for both parties to begin the process of a

Read More::

FDA Panel Protects Yaz Profits Over Women’s Safety

The US Food and Drug Administration (FDA) advisory committee voted 21-5 on Thursday that labeling on Bayer’s popular Yaz and similar birth control pills is inadequate and should be revised to better reflect the higher risk of blood clots associated with these drugs, compared with older oral contraceptives.  Ennis & Ennis, P.A. explains the panelists

Read More::

Should the FDA Recall Yaz and Yasmin?

The Food and Drug Administration’s (FDA) primary responsibility is to ensure that all medications it evaluates and approves are safe for public use. The pharmaceutical companies presumably extensively research and test new medications and provide this data to the FDA’s Center For Drug Evaluation Research (CDER).  Unfortunately, the CDER conducts no research or testing, rather

Read More::

 
© Ennis & Ennis, P.A.

Switch to our mobile site